| 中国学者近期发表的论文 |
|---|
| 1. | Body mass index and risk of primary liver cancer: a meta-analysis of prospective studies.
Author: Wang Y, Wang B, Shen F, Fan J, Cao H.
Journal: Oncologist. 2012;17(11):1461-8. doi: 10.1634/theoncologist.2012-0066. Epub 2012 Sep 6. | | 2. | Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in chinese patients with non-small cell lung cancer.
Author: Qian J, Qu HQ, Yang L, Yin M, Wang Q, Gu S, Wu Q, Zhao X, Wu W, Wu J, Tan X, Chen W, Wang H, Wang J, Fan W, Chen H, Han B, Lu D, Wei Q, Jin L.
Journal: Oncologist. 2012;17(12):1551-61. doi: 10.1634/theoncologist.2011-0419. Epub 2012 Jul 27. | | 3. | A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
Author: Liang JA, Sun LM, Lin MC, Chang SN, Sung FC, Muo CH, Kao CH.
Journal: Oncologist. 2012;17(7):986-91. doi: 10.1634/theoncologist.2011-0464. Epub 2012 Jun 20. | | 4. | More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies.
Author: Shen Z, Hoffman JD, Hao F, Pier E.
Journal: Oncologist. 2012;17(7):930-6. doi: 10.1634/theoncologist.2012-0033. Epub 2012 Jun 15. | | 5. | EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
Author: Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL.
Journal: Oncologist. 2012;17(7):978-85. doi: 10.1634/theoncologist.2011-0385. Epub 2012 Jun 6. | | 6. | Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy.
Author: Jun L, Zhenlin Y, Renyan G, Yizhou W, Xuying W, Feng X, Yong X, Kui W, Jian L, Dong W, Hongyang W, Lehua S, Mengchao W, Feng S.
Journal: Oncologist. 2012;17(7):963-9. doi: 10.1634/theoncologist.2011-0447. Epub 2012 May 31. | | 7. | Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.
Author: Yu KD, Liu GY, Zhou XY, Zhou Y, Wu J, Chen CM, Shen ZZ, Shao ZM.
Journal: Oncologist. 2012;17(6):792-800. doi: 10.1634/theoncologist.2011-0381. Epub 2012 May 4. | | 8. | A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Author: Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, Shames DS, Bu L, Kang YK.
Journal: Oncologist. 2016 Jul 8. pii: theoncologist.2016-0038. [Epub ahead of print] | | 9. | Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
Author: Tuerxun G, Yukesaier A, Lu L, Aierken K, Mijiti P, Jiang Y, Abulizi A, Zhang Y, Abuduxikuer G, Abulizi G, Li H.
Journal: Oncologist. 2016 Jul;21(7):825-31. doi: 10.1634/theoncologist.2015-0447. Epub 2016 Jun 17. | | 10. | Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Author: Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
Journal: Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5. |
|
